Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1M57I)

Drug Name

MK-2578 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Anemia	3A00-3A9Z	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Erythropoietin (EPO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LKA651	DMCFGP3	Diabetic macular edema	9B71.02	Phase 2	[3]
Erythropoietin-transfected autologous cell therapy	DMNZ6VA	Anemia	3A00-3A9Z	Phase 1/2	[4]
Long-acting erythropoietin conjugate	DM9OA35	Anemia	3A00-3A9Z	Phase 1	[5]
GC-1113	DMK96CE	Anemia	3A00-3A9Z	Phase 1	[6]
FC EPO	DMEX12T	Anemia	3A00-3A9Z	Discontinued in Phase 1	[7]
GLY-515n	DM0IKB4	Cerebrovascular ischaemia	8B1Z	Terminated	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT00968617) A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002). U.S. National Institutes of Health.
2	Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636.
3	Clinical pipeline report, company report or official report of Novartis.
4	Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Mol Ther. 2009 Feb;17(2):369-72.
5	Company report (Pharmexcil)
6	A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia. Arch Pharm Res. 2012 May;35(5):757-9.
7	Detection of EPO-Fc fusion protein in human blood: screening and confirmation protocols for sports drug testing. Drug Test Anal. 2012 Nov;4(11):818-29.
8	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027536)